These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 38816091)

  • 41. [Current status and measures for lung injuries in cancer treatment].
    Kudoh S; Yoshimura A
    Gan To Kagaku Ryoho; 2004 May; 31(5):679-84. PubMed ID: 15170972
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Malignant disease and the lung.
    Jenney ME
    Paediatr Respir Rev; 2000 Sep; 1(3):279-86. PubMed ID: 12531091
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Combined radiotherapy and chemotherapy: pulmonary side effects (author's transl)].
    Abbatucci JS
    Bull Cancer; 1981; 68(2):142-9. PubMed ID: 6165417
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Pulmonary toxicity and cancer treatment.
    Fennell DA; Rudd RM
    Hosp Med; 2004 Aug; 65(8):462-5. PubMed ID: 15330346
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Interstitial Lung Disease Induced by Anti-ERBB2 Antibody-Drug Conjugates: A Review.
    Tarantino P; Modi S; Tolaney SM; Cortés J; Hamilton EP; Kim SB; Toi M; Andrè F; Curigliano G
    JAMA Oncol; 2021 Dec; 7(12):1873-1881. PubMed ID: 34647966
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial.
    Shaverdian N; Lisberg AE; Bornazyan K; Veruttipong D; Goldman JW; Formenti SC; Garon EB; Lee P
    Lancet Oncol; 2017 Jul; 18(7):895-903. PubMed ID: 28551359
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Endocrine side-effects of new anticancer therapies: Overall monitoring and conclusions.
    Castinetti F; Albarel F; Archambeaud F; Bertherat J; Bouillet B; Buffier P; Briet C; Cariou B; Caron P; Chabre O; Chanson P; Cortet C; Do Cao C; Drui D; Haissaguerre M; Hescot S; Illouz F; Kuhn E; Lahlou N; Merlen E; Raverot V; Smati S; Verges B; Borson-Chazot F
    Ann Endocrinol (Paris); 2018 Oct; 79(5):591-595. PubMed ID: 30056975
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Drug-induced pulmonary lesions].
    Dragomir D; Popescu V
    Pediatrie (Bucur); 1992; 41(3):36-45. PubMed ID: 1327232
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Surviving malignant disease. Medical and oncological aspects.
    Price LA
    Br J Hosp Med; 1983 Jul; 30(1):8-12. PubMed ID: 6192863
    [No Abstract]   [Full Text] [Related]  

  • 50. Pulmonary toxicity from novel antineoplastic agents.
    Dimopoulou I; Bamias A; Lyberopoulos P; Dimopoulos MA
    Ann Oncol; 2006 Mar; 17(3):372-9. PubMed ID: 16291774
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Drug-induced interstitial lung disease in tyrosine kinase inhibitor therapy for non-small cell lung cancer: a review on current insight.
    Min JH; Lee HY; Lim H; Ahn MJ; Park K; Chung MP; Lee KS
    Cancer Chemother Pharmacol; 2011 Nov; 68(5):1099-109. PubMed ID: 21913033
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Drug-related problems with targeted/immunotherapies at an oncology outpatient clinic.
    Kucuk E; Bayraktar-Ekincioglu A; Erman M; Kilickap S
    J Oncol Pharm Pract; 2020 Apr; 26(3):595-602. PubMed ID: 31342849
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Drug-induced interstitial lung diseases associated with molecular-targeted anticancer agents.
    Gemma A
    J Nippon Med Sch; 2009 Feb; 76(1):4-8. PubMed ID: 19305103
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Association between glucose intolerance and chemotherapy-induced lung injury in patients with lung cancer and interstitial lung disease.
    Otani T; Yamaguchi K; Nakao S; Sakamoto S; Horimasu Y; Masuda T; Miyamoto S; Nakashima T; Iwamoto H; Fujitaka K; Hamada H; Hattori N
    Cancer Chemother Pharmacol; 2021 Nov; 88(5):857-865. PubMed ID: 34350479
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Drug-induced respiratory disease in patients with hematological diseases.
    Camus P; Costabel U
    Semin Respir Crit Care Med; 2005 Oct; 26(5):458-81. PubMed ID: 16267698
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Pulmonary toxicity of antineoplastic drugs.
    Batist G; Andrews JL
    JAMA; 1981 Sep; 246(13):1449-53. PubMed ID: 7265453
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Pemetrexed-related interstitial lung disease reported from post marketing surveillance (malignant pleural mesothelioma/non-small cell lung cancer).
    Tomii K; Kato T; Takahashi M; Noma S; Kobashi Y; Enatsu S; Okubo S; Kobayashi N; Kudoh S
    Jpn J Clin Oncol; 2017 Apr; 47(4):350-356. PubMed ID: 28158568
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Final safety and efficacy of erlotinib in the phase 4 POLARSTAR surveillance study of 10 708 Japanese patients with non-small-cell lung cancer.
    Gemma A; Kudoh S; Ando M; Ohe Y; Nakagawa K; Johkoh T; Yamazaki N; Arakawa H; Inoue Y; Ebina M; Kusumoto M; Kuwano K; Sakai F; Taniguchi H; Fukuda Y; Seki A; Ishii T; Fukuoka M
    Cancer Sci; 2014 Dec; 105(12):1584-90. PubMed ID: 25287435
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Distinctive impact of pre-existing interstitial lung disease on the risk of chemotherapy-related lung injury in patients with lung cancer.
    Ozawa Y; Akahori D; Koda K; Abe T; Hasegawa H; Matsui T; Tanahashi M; Niwa H; Yamada K; Yokomura K; Suda T
    Cancer Chemother Pharmacol; 2016 May; 77(5):1031-8. PubMed ID: 27048413
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The Impact of Dermatologic Adverse Events on the Quality of Life of Oncology Patients: A Review of the Literature.
    Belzer A; Pach JJ; Valido K; Leventhal JS
    Am J Clin Dermatol; 2024 May; 25(3):435-445. PubMed ID: 38366030
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.